Media coverage about Emergent Biosolutions (NYSE:EBS) has been trending somewhat positive this week, according to Accern. Accern rates the sentiment of press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Emergent Biosolutions earned a news sentiment score of 0.18 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 46.4151767076176 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the news headlines that may have effected Accern’s rankings:
- Emergent BioSolutions Reports Fourth Quarter and Twelve Months 2017 Financial Results NYSE:EBS (menafn.com)
- Emergent Biosolutions beats 4Q profit forecasts (finance.yahoo.com)
- Emergent Biosolutions (EBS) Announces Quarterly Earnings Results (americanbankingnews.com)
- Emergent BioSolutions (EBS) Presents At RBC Capital Markets Global Healthcare Conference – Slideshow (seekingalpha.com)
- What You Must Know About Emergent BioSolutions Inc’s (NYSE:EBS) 12.20% ROE (finance.yahoo.com)
A number of equities analysts recently issued reports on the stock. Zacks Investment Research lowered shares of Emergent Biosolutions from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 19th. Goldman Sachs Group initiated coverage on shares of Emergent Biosolutions in a research note on Wednesday, January 24th. They issued a “neutral” rating and a $55.00 target price on the stock. Finally, Chardan Capital boosted their target price on shares of Emergent Biosolutions from $47.00 to $53.00 and gave the company a “buy” rating in a research note on Tuesday, January 16th. One analyst has rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average target price of $51.00.
Emergent Biosolutions (NYSE:EBS) last posted its quarterly earnings data on Thursday, February 22nd. The biopharmaceutical company reported $0.74 EPS for the quarter, topping the Zacks’ consensus estimate of $0.70 by $0.04. The company had revenue of $193.80 million for the quarter, compared to analyst estimates of $189.96 million. Emergent Biosolutions had a return on equity of 15.20% and a net margin of 15.60%. The firm’s quarterly revenue was up 27.8% on a year-over-year basis. During the same period in the previous year, the firm earned $0.74 earnings per share. equities research analysts expect that Emergent Biosolutions will post 1.85 earnings per share for the current fiscal year.
In other news, Director Zsolt Harsanyi sold 7,000 shares of the company’s stock in a transaction on Thursday, December 7th. The stock was sold at an average price of $42.47, for a total transaction of $297,290.00. Following the transaction, the director now owns 37,077 shares of the company’s stock, valued at approximately $1,574,660.19. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Chairman Fuad El-Hibri sold 47,983 shares of the company’s stock in a transaction on Wednesday, November 29th. The shares were sold at an average price of $41.88, for a total value of $2,009,528.04. Following the transaction, the chairman now directly owns 1,550,216 shares in the company, valued at approximately $64,923,046.08. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 125,722 shares of company stock valued at $5,604,541. Corporate insiders own 16.50% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Emergent Biosolutions (EBS) Given Media Impact Score of 0.18” was first published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://stocknewstimes.com/2018/02/23/somewhat-positive-media-coverage-somewhat-unlikely-to-impact-emergent-biosolutions-ebs-share-price.html.
About Emergent Biosolutions
Emergent BioSolutions Inc is a life sciences company. The Company focuses on protecting and enhancing life by providing specialty products for civilian and military populations that address accidental, intentional and naturally emerging public health threats. It focuses on developing, manufacturing and commercializing medical countermeasures that address public health threats (PHTs).
Receive News & Ratings for Emergent Biosolutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emergent Biosolutions and related companies with MarketBeat.com's FREE daily email newsletter.